Mechanisms of Tumor Induction by Peroxisome Proliferators

  • P. Bentley
  • F. Bieri
  • S. Muakkassah-Kelly
  • W. Stäubli
  • F. Waechter
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 12)


Peroxisome proliferation is observed as a response, particularly in the liver, to subchronic treatment of rodents with a variety of structurally diverse compounds. This characteristic hepatomegaly was first described in rats treated with the hypolipidemic agent Clofibrate (Hess et al. 1965) and has subsequently been observed in rodents treated with other hypolipidemic agents (Cayen 1985), antiemetics and anti-inflammatories (Ishii and Suga 1979), a leukotriene D4 antagonist (Eacho et al. 1985), herbicides (Moody and Hammock 1987), and plasti-cizers (Warren et al. 1982). Generally treatment of rodents with such compounds results in marked increases in liver weight within a few days, as a consequence of both hyperplasia and hypertrophy. At the subcellular level the hypertrophic hepatocytes show a marked proliferation of the peroxisomal compartment, accompanied by an increase in the amount of smooth endoplasmic reticulum. Biochemically these changes are reflected as an induction of peroxisomal and microsomal enzymes (Bentley et al. 1987a). Lifelong treatment of rodents with several peroxisome proliferators was associated with increased incidences of hepatocellular carcinomas, a finding which led Reddy et al. (1980) to conclude that peroxisome proliferators form a unique class of hepatocarcinogens. These authors proposed a causal link between peroxisome proliferation and carcinogenicity (Fig.1 (discussed below).


Peroxisome Proliferators Tumor Induction B6C3F1 Mouse Hypolipidemic Agent Alkaline Elution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beer DG, Schwarz M, Sawada N, Pitot HC (1986) Expression of H-ras and c-myc protoon-cogenes in isolated γ-glutamyl transpeptidase-positive rat hepatocytes and in hepatocellular carcinomas induced by diethylnitrosamine. Cancer Res 46:2435–2441PubMedGoogle Scholar
  2. Bentley P, Bieri F, Mitchell F, Waechter F, Stäubli W (1987a) Investigations on the mechanism of liver tumour induction by peroxisome proliferators. Arch Toxicol, Suppl 10:157–161CrossRefGoogle Scholar
  3. Bentley P, Waechter F, Bieri F, Stäubli W (1987b) Risks and benefits of agents which induce hepatic peroxisome proliferation. In: Fahimi HD, Sies H (eds) Peroxisomes in biology and medicine. Springer, Berlin Heidelberg New York, pp 309–314CrossRefGoogle Scholar
  4. Berridge MT (1987) Inositol lipids and cell proliferation. Biochim. Biophys. Acta 907:33–45PubMedGoogle Scholar
  5. Bieri F, Bentley P, Waechter F, Stäubli W (1984) Use of primary cultures of adult rat hepatocytes to investigate mechanisms of action of nafenopin, a hepatocarcinogenic peroxisome proliferator. Carcinogenesis 5:1033–1039PubMedCrossRefGoogle Scholar
  6. Bieri F, Bentley P, Waechter F, Stäubli W (1986) Mitogenicity of peroxisome proliferators in monolayers of adult rat hepatocytes. Food Chem Toxicol 24:709CrossRefGoogle Scholar
  7. Butterworth BE, Bermudez E, Smith-Oliver T, Earle L, Cattley R, Martin J, Popp JA, Strom S, Jirtle R, Michalopoulas G (1984) Lack of genotoxic activity of di(2-ethylhexyl)phthalate (DEHP) in rat and human hepatocytes. Carcinogenesis 5: 1329–1335PubMedCrossRefGoogle Scholar
  8. Cayen MN (1985) Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmac Ther 29:157–204.CrossRefGoogle Scholar
  9. Cerutti (1985) Prooxidant states and tumour promotion. Science 227:375–387PubMedCrossRefGoogle Scholar
  10. Eacho PI, Foxworthy PS, Johnson WD, VanLier RBL (1985) Chracterization of the liver enlargement induced by compound LY 171883 in rats. Fund Appl Toxicol 5:794–803CrossRefGoogle Scholar
  11. Elliot BM, Dodd NJF, Elcombe CR (1986) Increased hydroxyl radical production in liver peroxisomal fractions from rats treated with peroxisome proliferators. Carcinogenesis 7:795–799CrossRefGoogle Scholar
  12. Fahl WE, Lalwani ND, Watanabe T, Goel SK, Reddy JK (1984) DNA damage related to increased hydrogen peroxide generation by hypolipidaemic drug-induced liver peroxisomes. Proc Natl Acad Sc USA 81:7827–7830CrossRefGoogle Scholar
  13. Fitzgerald JE, Sanyer JL, Schardein JL, Lahe RS, McGuire EJ, de la Iglesia FA (1981) Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. J Natl Cancer Inst 67:1105–110PubMedGoogle Scholar
  14. Furukawa K, Numoto S, Furuya F, Furukawa NT, Williams GM (1985) Effects of the he-patocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital. Cancer Res 45:5011–5019PubMedGoogle Scholar
  15. Glauert HP, Beer D, Rao MS; Schwarz M, Xu D, Goldsworthy TL, Coloma J, Pitot HC (1986) Induction of altered hepatic foci in rats by the administration of hypolipidemic peroxisome proliferators alone or following a single dose of diethylnitrosamine. Cancer Res 46:4601–4606PubMedGoogle Scholar
  16. Greaves P, Irisarri E, Monro AM (1986) Hepatic foci of cellular and enzymic alteration and nodules in rats treated with Clofibrate of diethylnitrosamine followed by phenobarbital: Their rate of onset and their reversibility. J Natl Cancer Inst 76:475–484PubMedGoogle Scholar
  17. Goel SK, Lalwani ND, Fahl WE, Reddy JK (1985) Lack of covalent binding of the peroxisome proliferators nafenopin and Wy 14–643 to DNA in vivo and in vitro. Toxical Lett 24:37–43CrossRefGoogle Scholar
  18. Hess R, Stäubli W, Riess W (1965) Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature 208:856–858PubMedCrossRefGoogle Scholar
  19. Hsieh LL, Hsiao W-L, Peraino C, Maronpot RR, Weinstein IB (1987) Expression of retroviral sequences and oncogenes in rat liver tumours induced by diethylnitrosamine. Cancer Res 47:3421–3424PubMedGoogle Scholar
  20. Ishii H, Suga T (1979) Clofibrate-like effects of acetylsalicylic acid on peroxisomes and on hepatic and serum triglyceride levels. Biochem Pharmacol 28:2829–2833PubMedCrossRefGoogle Scholar
  21. Jones DP, Ekloew L, Thor H, Orrenius S (1981) Metabolism of hydrogen peroxide in isolated hepatocytes: Relative contributions of endogenously generated H2O2. Arch Biochem Biophys 210:505–516PubMedCrossRefGoogle Scholar
  22. Moody DE, Hammock BD (1987) The effect of Tridiphane (2-(3,5-dichlorophenyl)-2–2,2,2-trichloroethyl) oxirane on hepatic epoxide-metabolising enzymes: Indications of peroxisome proliferation. Toxicol Appl Pharmacol 89:37–48PubMedCrossRefGoogle Scholar
  23. Numoto S, Furukawa K, Furuya K, Williams GM (1984) Effects of the hepatocarcinogenic peroxisome-proliferating hypolipidemic agents Clofibrate and nafenopin on the rat liver membrane enzymes γ-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis. Carcinogenesis 5:1603–1611PubMedCrossRefGoogle Scholar
  24. Popp JA, Garvey LK, Hamm TE, Swenberg JA (1985) Lack of hepatic promotional activity by the peroxisomal proliferating hepatocarcinogen di(2-ethylhexyl)phthalate. Carcinogenesis 6.141–144PubMedCrossRefGoogle Scholar
  25. Rao MS, Lalwani ND, Scarpelli DG, Reddy JK (1982) The absence of γ-glutamyltranspeptidase activity in putative preneoplastic lesions and in hepatocellular carcinomas induced in rats by the hypolipidemic peroxisome proliferator Wy 14–634. Carcinogenesis 3:1231–1233PubMedCrossRefGoogle Scholar
  26. Reddy JK, Azarnoff DL, Hignite CE (1980) Hypolipidemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283:397–398PubMedCrossRefGoogle Scholar
  27. Reddy JK, Lalwani ND, Reddy MK, Qureshi SA (1982) Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res 42:259–266PubMedGoogle Scholar
  28. Reddy JK, Lalwani ND, Qureshi SA, Reddy MK, Moehle CM (1984) Induction of hepatic peroxisomal proliferation in non-rodent species including primates. Am J Pathol 114:171–183PubMedGoogle Scholar
  29. Schulte-Hermann R, Ohde G, Schuppler J, Timmermann-Trosiener I (1981) Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds and nafenopin. Cancer Res 41:2556–2562PubMedGoogle Scholar
  30. Stäubli W, Bentley P, Biery F, Froehlich E, Waechter F (1984) Inhibitory effect of nafenopin upon development of nitrosamine-induced enzyme-altered foci within the liver. Carcinogenesis 5:41–46PubMedCrossRefGoogle Scholar
  31. Thompson NL, Mead JE, Braun L, Goyette M, Shank PR, Fausto N (1986) Sequential pro-tooncogene expression during rat liver regeneration. Cancer Res 46:3111–3117PubMedGoogle Scholar
  32. Tomaszewski KE, Agarwal DK, Melnick RL (1986) In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators. Carcinogenesis 7:1871–1876PubMedCrossRefGoogle Scholar
  33. Von Däniken A, Lutz WK, Schlatter C (1981) Lack of covalent binding to rat liver DNA of the hypolipidaemic drugs Clofibrate and fenofibrate. Toxicol Lett 7:305–310CrossRefGoogle Scholar
  34. Ward JM, Ohsima M, Lynch P, Riggs C (1984) Di(2-ethylhexyl)phthalate but not phenobarbital promotes iV-nitrosodiethylamine-initiated hepatocellular proliferative lesions after short-term exposure in male B6C3F1 mice. Cancer Letts 24:49–55CrossRefGoogle Scholar
  35. Warren JR, Lalwani ND, Reddy JK (1982) Phthalate esters as peroxisome proliferator carcinogens. Environ Health Perspect 45:35–40PubMedCrossRefGoogle Scholar
  36. Warren JR, Simmon VF, Reddy JK (1980) Properties of hypolipidemic peroxisome proliferators in the lymphocyte [3H]thymidine and Salmonella mutagenesis assays. Cancer Res. 40:36–41PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • P. Bentley
    • 1
  • F. Bieri
    • 1
  • S. Muakkassah-Kelly
    • 1
  • W. Stäubli
    • 1
  • F. Waechter
    • 1
  1. 1.Ciba-Geigy LimitedCentral Toxicology UnitBaselSwitzerland

Personalised recommendations